Atlas Trials

Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT03719989 · UNKNOWN

Trial details

NCT number
NCT03719989
Sponsor
Seoul National University Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell LymphomaRelapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
Start date
2018-12-01
Primary completion
2021-11-30
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.